Browsing Radiotherapy and Imaging by author "Huddart, Robert"
Now showing items 1-20 of 108
-
A Canadian approach to the regionalization of testis cancer: A review.
Nason, GJ; Wood, LA; Huddart, RA; Albers, P; Rendon, RA; et al. (2020-10)At the Canadian Testis Cancer Workshop, the rationale and feasibility of regionalization of testis cancer care were discussed. The two-day workshop involved urologists, medical and radiation oncologists, pathologists, ... -
A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer.
Portner, R; Bajaj, A; Elumalai, T; Huddart, R; Murthy, V; et al. (ELSEVIER IRELAND LTD, 2021-08-19)Bladder preservation with trimodality treatment (TMT) is an alternative strategy to radical cystectomy (RC) for the management of localised muscle invasive bladder cancer (MIBC). TMT comprises of transurethral resection ... -
A Randomised Phase 2 Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor-prognosis Germ Cell Tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604)
Huddart, RA; Gabe, R; Cafferty, FH; Pollock, P; White, JD; et al. (2015-03-01) -
A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin.
Jones, R; Crabb, S; Chester, J; Elliott, T; Huddart, R; et al. (WILEY, 2020-05-19)OBJECTIVES: To assess the efficacy and tolerability of the dual epidermal growth factor receptor/vascular endothelial growth factor receptor inhibitor, vandetanib, in combination with carboplatin and gemcitabine in the ... -
A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3).
Shamash, J; Sarker, S-J; Huddart, R; Harland, S; Joffe, JK; et al. (OXFORD UNIV PRESS, 2017-06-01)BACKGROUND: Bleomycin is an integral part of combination chemotherapy in germ cell tumours. Pulmonary toxicity often necessitates drug cessation and death occurs in 1%-2% of patients. A continuous infusion of bleomycin ... -
A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact.
Macinnis, RJ; Antoniou, AC; Eeles, RA; Severi, G; Al Olama, AA; et al. (WILEY, 2011-07-18)Genome wide association studies have identified several single nucleotide polymorphisms (SNPs) that are independently associated with small increments in risk of prostate cancer, opening up the possibility for using such ... -
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial.
Hussain, SA; Lester, JF; Jackson, R; Gornall, M; Qureshi, M; et al. (ELSEVIER SCIENCE INC, 2022-05-01)BACKGROUND: Recurrence is common after neoadjuvant chemotherapy and radical treatment for muscle-invasive bladder cancer. We investigated the effect of adding nintedanib to neoadjuvant chemotherapy on response and survival ... -
Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP.
Huddart, RA; Reid, AM (HINDAWI LTD, 2018-01-01)Testicular germ cell tumours are the commonest tumours of young men and are broadly managed either as pure seminomas or as 'nonseminomas'. The management of Stage 1 nonseminomatous germ cell tumours (NSGCTs), beyond surgical ... -
Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.
Abu Zaid, M; Dinh, PC; Monahan, PO; Fung, C; El-Charif, O; et al. (HARBORSIDE PRESS, 2019-05-01)BACKGROUND: This study examined the prevalence of hypogonadism, its clinical and genetic risk factors, and its relationship to adverse health outcomes (AHOs) in North American testicular cancer survivors (TCS) after modern ... -
Assessing Bladder Radiotherapy Response With Quantitative Diffusion-Weighted Magnetic Resonance Imaging Analysis.
Hafeez, S; Koh, M; Jones, K; El Ghzal, A; D'Arcy, J; et al. (ELSEVIER SCIENCE LONDON, 2022-05-06)AIMS: Radiotherapy with radiosensitisation offers opportunity for cure with organ preservation in muscle-invasive bladder cancer (MIBC). Treatment response assessment and follow-up are reliant on regular endoscopic evaluation ... -
Bladder Radiotherapy: Is Cinderella Ready for the Ball?
Huddart, RA (ELSEVIER SCIENCE LONDON, 2021-06-01) -
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).
Kelly, JD; Tan, WS; Porta, N; Mostafid, H; Huddart, R; et al. (ELSEVIER SCIENCE BV, 2019-04-01)BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) has a significant risk of recurrence despite adjuvant intravesical therapy. OBJECTIVE: To determine whether celecoxib, a cyclo-oxygenase 2 inhibitor, reduces the risk ... -
Chemical- and radiation-induced haemorrhagic cystitis: current treatments and challenges.
Payne, H; Adamson, A; Bahl, A; Borwell, J; Dodds, D; et al. (WILEY, 2013-11-01)• To review the published data on predisposing risk factors for cancer treatment-induced haemorrhagic cystitis (HC) and the evidence for the different preventive and therapeutic measures that have been used in order to ... -
Circulating Tumour DNA in Muscle-Invasive Bladder Cancer.
Tan, MP; Attard, G; Huddart, RA (MDPI, 2018-08-29)Circulating tumour DNA (ctDNA) is an attractive tool in cancer research, offering many advantages over tissue samples obtained using traditional biopsy methods. There has been increasing interest in its application to ... -
Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms.
El Charif, O; Mapes, B; Trendowski, MR; Wheeler, HE; Wing, C; et al. (AMER ASSOC CANCER RESEARCH, 2019-07-01)PURPOSE: Cisplatin, a commonly used chemotherapeutic, results in tinnitus, the phantom perception of sound. Our purpose was to identify the clinical and genetic determinants of tinnitus among testicular cancer survivors ... -
Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.
Huddart, RA; Birtle, A; Maynard, L; Beresford, M; Blazeby, J; et al. (WILEY, 2017-11-01)OBJECTIVES: To test the feasibility of a randomised trial in muscle-invasive bladder cancer (MIBC) and compare outcomes in patients who receive neoadjuvant chemotherapy followed by radical cystectomy (RC) or selective ... -
Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic - Rapid Review.
Patel, K; Choudhury, A; Hoskin, P; Varughese, M; James, N; et al. (ELSEVIER SCIENCE LONDON, 2020-06-01)The current COVID-19 pandemic presents a substantial obstacle to cancer patient care. Data from China as well as risk models suppose that cancer patients, particularly those on active, immunosuppressive therapies are at ... -
Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer.
Huddart, R; Hafeez, S; Lewis, R; McNair, H; Syndikus, I; et al. (ELSEVIER SCIENCE INC, 2021-06-01)PURPOSE: Hypofractionated radiation therapy can be used to treat patients with muscle-invasive bladder cancer unable to have radical therapy. Toxicity is a key concern, but adaptive plan-of the day (POD) image-guided ... -
Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment.
Hafeez, S; McDonald, F; Lalondrelle, S; McNair, H; Warren-Oseni, K; et al. (ELSEVIER SCIENCE INC, 2017-05-01)PURPOSE AND OBJECTIVES: We report on the clinical outcomes of a phase 2 study assessing image guided hypofractionated weekly radiation therapy in bladder cancer patients unsuitable for radical treatment. METHODS AND ... -
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.
Crabb, SJ; Martin, K; Abab, J; Ratcliffe, I; Thornton, R; et al. (ELSEVIER SCI LTD, 2017-12-01)BACKGROUND: Cisplatin is one of the most ototoxic chemotherapy drugs, resulting in a permanent and irreversible hearing loss in up to 50% of patients. Cisplatin and gentamicin are thought to damage hearing through a common ...